New R&D collaboration with Nobel Prize winner
Posted by
26-Feb-2013
Partnership: In the health and medicines sector these days, everybody is talking about it. Collaboration is essential if we are to find new therapies which improve the lives of people with severe diseases.
At UCB, we have embraced the need to build relationships with universities and patient groups. This allows us to develop new patient-support tools and to help patient communities to be heard. It also means working with leading experts at Oxford and Harvard on cutting-edge science that can deliver future success.
Last week, a group of interdisciplinary NewMedicines researchers, Tom Ceska, Martyn Wood, Christophe Genicot, Giles Saville and Florence Lebon sealed a research deal with ConfometRX, a structural biology company founded by Stanford University professor and Nobel Prize winner Brian Kobilka.
Under this collaboration, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. GPCRs are the largest family of signaling proteins in the human genome. They are involved in virtually all physiological processes and represent the single largest target class for medicines on the market.
Professor Brian Kobilka won the Nobel Prize for chemistry for his studies of G-protein-coupled receptors and we are delighted to join forces with ConfometRX as part of this exciting two-year research agreement.
The partnership, which includes an up-front payment, research funding, and success-based milestones, allows us to develop our expertise in this area and nicely complements the work of our drug design team in Slough.
We are proud that UCB continues to partner with the best, and that the best continue to partner with UCB.
At UCB, we have embraced the need to build relationships with universities and patient groups. This allows us to develop new patient-support tools and to help patient communities to be heard. It also means working with leading experts at Oxford and Harvard on cutting-edge science that can deliver future success.
Last week, a group of interdisciplinary NewMedicines researchers, Tom Ceska, Martyn Wood, Christophe Genicot, Giles Saville and Florence Lebon sealed a research deal with ConfometRX, a structural biology company founded by Stanford University professor and Nobel Prize winner Brian Kobilka.
Under this collaboration, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. GPCRs are the largest family of signaling proteins in the human genome. They are involved in virtually all physiological processes and represent the single largest target class for medicines on the market.
Professor Brian Kobilka won the Nobel Prize for chemistry for his studies of G-protein-coupled receptors and we are delighted to join forces with ConfometRX as part of this exciting two-year research agreement.
The partnership, which includes an up-front payment, research funding, and success-based milestones, allows us to develop our expertise in this area and nicely complements the work of our drug design team in Slough.
We are proud that UCB continues to partner with the best, and that the best continue to partner with UCB.
Leave a Comment